Novo Nordisk Secures Twin EU Backing for Rare-Disease Portfolio Ahead of London Strategy Day
Published on 09/19/2026 at 07:50 | Editorial boerse-global.de
Novo Nordisk closed out a busy week of regulatory and corporate news with two separate endorsements from the European Medicines Agency's human medicines committee, positioning the Danish drugmaker to expand its footprint in growth disorders and hemophilia just as management prepares to face investors in London.
The Committee for Medicinal Products for Human Use (CHMP) recommended on Friday that Sogroya be approved for children with idiopathic short stature (ISS), making it the first and only once-weekly growth hormone cleared for that indication in Europe. The positive opinion rests on Phase 3 data from the REAL8 trial, in which the therapy proved non-inferior to daily growth hormone injections as measured by mean annual growth velocity after 52 weeks. ISS affects as many as 3 percent of children worldwide, according to study figures — a sizable population for a specialized product.
That vote complements two earlier CHMP opinions issued in May covering SGA and Noonan syndrome. The European Commission is expected to rule on all three indications later in 2026. Sogroya is already authorized in Europe for growth hormone deficiency in adults and in children aged three and older.
Hemophilia A Candidate Also Clears the Panel
During the same sitting, held September 14–17, the committee threw its weight behind Frehemgo (denecimig) as a long-acting prophylaxis for hemophilia A, with dosing intervals ranging from once weekly to once monthly. The drug is intended for both adults and children and can be administered via a prefilled pen on a monthly, biweekly, or weekly schedule.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Supporting the opinion, Phase 3b data from the FRONTIER5 study were published Thursday in the Journal of Thrombosis and Haemostasis. The research documents the tolerability of denecimig in hemophilia A patients who switched directly from emicizumab, reinforcing the company's scientific footing in the indication.
Pipeline Deals Span Oral Drugs and AI
Beyond the regulatory arena, Novo Nordisk has been busy assembling partnerships. A collaboration with Orbis Medicines ApS targets novel oral macrocycle therapeutics for cardiometabolic disease, with milestone payments and compensation reaching up to USD 1.4 billion. Days earlier, the group disclosed a tie-up with AI developer Anthropic centered on the Claude frontier models and the Claude Science Workbench environment, technology intended to speed up drug discovery and accelerate software development across the research organization.
The operational momentum follows a brand overhaul unveiled Monday. The company will now market itself under the single name Novo with the tagline "Lasting Health Starts Now," while the legal entity Novo Nordisk A/S remains unchanged.
Buyback Keeps Rolling
Management has also pressed ahead with capital returns. Under the current program, a total of 33,084,179 own B shares were repurchased between February 4 and the September 11 cutoff date.
Pressure Mounts Before Monday's Investor Meeting
All of this lands as Novo Nordisk faces growing demands for concrete strategic answers. On Monday the company hosts a Capital Markets Day in London, where CEO Mike Doustdar and CFO Karsten Munk Knudsen will meet investors. Analysts and major shareholders are pressing for clear financial targets and greater pipeline transparency — issues that have taken on added weight given looming patent expirations on key products and recent disappointing trial results. Doustdar has said he wants to "rethink" the company's obesity strategy to hold off rival Eli Lilly.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Competitive pressure is intensifying as exclusivity on semaglutide erodes. Sandoz received Canadian health authority approval Friday for a generic version of the compound, after Novo Nordisk lost its patent on the active ingredient last year. While no material earnings contribution from the Canadian generic entry is expected for 2026, the pattern is likely to repeat in other markets.
The shares ended Friday at EUR 37.58, down 15 percent since the start of the year. They now sit roughly 31 percent below their 52-week high of EUR 54.86, reached at the end of January, with the 200-day moving average of EUR 40.00 also above the current level.
The CHMP nods deliver tangible pipeline progress, yet they are unlikely to settle the deeper questions on growth prospects and competitive standing that Monday's Capital Markets Day must address.
Ad
Novo Nordisk Stock: New Analysis - 19 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
